BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35772170)

  • 1. The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease.
    Ay C; Pabinger I; Kovacevic KD; Gelbenegger G; Schörgenhofer C; Quehenberger P; Jilma-Stohlawetz P; Sunder-Plassman R; Gilbert JC; Zhu S; Jilma B; Derhaschnig U
    Blood Adv; 2022 Sep; 6(18):5467-5476. PubMed ID: 35772170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
    Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
    J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
    Jilma-Stohlawetz P; Knöbl P; Gilbert JC; Jilma B
    Thromb Haemost; 2012 Aug; 108(2):284-90. PubMed ID: 22740102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
    Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
    Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Willebrand factor multimers in plasma.
    Takimoto Y; Imanaka F
    Int J Hematol; 1999 Aug; 70(2):127-31. PubMed ID: 10497852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
    Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
    Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ay C, Pabinger I, Kovacevic KD, et al. The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. Blood Adv. 2022;6(18):5467-5476.
    Blood Adv; 2023 Jun; 7(11):2656. PubMed ID: 37310761
    [No Abstract]   [Full Text] [Related]  

  • 17. The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial.
    Kovacevic KD; Grafeneder J; Schörgenhofer C; Gelbenegger G; Gager G; Firbas C; Quehenberger P; Jilma-Stohlawetz P; Bileck A; Zhu S; Gilbert JC; Beliveau M; Jilma B; Derhaschnig U
    Haematologica; 2022 Sep; 107(9):2121-2132. PubMed ID: 34818873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on type 2B von Willebrand disease.
    Mikhail S; Aldin ES; Streiff M; Zeidan A
    Expert Rev Hematol; 2014 Apr; 7(2):217-31. PubMed ID: 24521271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases].
    Guermazi S; Conard J; Samama MM; Dellagi K
    Pathol Biol (Paris); 2006 Apr; 54(3):159-65. PubMed ID: 16176858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.